Skip to main content
About
Management
Board of Directors
Scientific Advisory Board
Business Development
Contact Us
Pipeline
Programs
KRAS G12C Inhibitor (MRTX849)
Sitravatinib (MGCD516)
Posters/Publications
Clinical Trials
Mirati Sponsored Trials
Collaboration Trials
Expanded Access Policy
(Compassionate Use)
Careers
Mission & Values
Investors
Overview
News Releases
Events & Presentations
Stock Information
Analyst Coverage
Financials & Filings
Corporate Governance
Investor FAQs
IR Contact
Emails Alerts
News Releases
Normal
Press release year list
2021
2020
2019
2018
2017
2016
2015
2014
2013
12/09/2013
Mirati Presents Clinical Response Results of Mocetinostat in Combination with Azacitidine as a Treatment for MDS
Download
PDF format download (opens in new window)
12/02/2013
Updated Presentation Time: Mirati Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
Download
PDF format download (opens in new window)
11/22/2013
Mirati Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
Download
PDF format download (opens in new window)
11/12/2013
Mirati Therapeutics Reports Third Quarter 2013 Financial Results
Download
PDF format download (opens in new window)
11/08/2013
Mirati Therapeutics to Present Data on Phase 1/2 Trial of Mocetinostat at the 55th American Society of Hematology Annual Meeting
10/23/2013
Mirati Therapeutics Prices Public Offering Of Common Stock
Download
PDF format download (opens in new window)
10/16/2013
Mirati Therapeutics Announces Public Offering Of Common Stock
Download
PDF format download (opens in new window)
9/04/2013
Mirati Therapeutics Appoints Isan Chen as Chief Medical and Development Officer and Adds Craig Johnson to Board of Directors
Download
PDF format download (opens in new window)
8/12/2013
Mirati Therapeutics Reports Second Quarter 2013 Financial Results
Download
PDF format download (opens in new window)
7/19/2013
Mirati Therapeutics to Voluntarily Delist from TSX
Download
PDF format download (opens in new window)
7/15/2013
Mirati Therapeutics to Commence Trading on the NASDAQ
Download
PDF format download (opens in new window)
6/28/2013
Mirati Therapeutics and MethylGene Announce Completion of Plan of Arrangement
Download
PDF format download (opens in new window)
5/09/2013
MethylGene Announces Plan to Reincorporate in the United States as Mirati Therapeutics, Inc. and List on the NASDAQ
Download
PDF format download (opens in new window)